A‑1210477, a selective MCL‑1 inhibitor, overcomes ABT‑737 resistance in AML

Wang,Qing; Hao,Siguo

doi:10.3892/ol.2019.10891

A‑1210477, a selective MCL‑1 inhibitor, overcomes ABT‑737 resistance in AML

Authors:
- Qing Wang
- Siguo Hao
View Affiliations

Affiliations: Department of Hematology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200092, P.R. China
Published online on: September 19, 2019 https://doi.org/10.3892/ol.2019.10891
Pages: 5481-5489
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Acute myeloid leukemia (AML) is one of the most common hematological malignancies. It is difficult to treat since it easily develops resistance to therapeutic drugs. Myeloid cell leukemia 1 (MCL‑1), BCL‑2 and BCL‑XL, which belong to the anti‑apoptotic group of proteins in the BCL‑2 family, are overexpressed in AML. The effects of inhibitors that target anti‑apoptotic proteins of the BCL‑2 family in AML were evaluated in the present study. MCL‑1 protein levels of HL60, MOLM13, OCI‑AML3 and MV4‑11 cell lines were investigated. Furthermore, following treatment with MCL‑1‑selective antagonist A‑1210477 and/or BCL‑2/BCL‑XL antagonist ABT‑737, cell viability was detected. The chimera rate of human CD45(+) cells of bone marrow from mouse models was analyzed via flow cytometry and immunohistochemistry using murine tissues (lung, spleen and liver). The data revealed that the HL‑60 cell line, which exhibited a low MCL‑1 protein level, and MOLM‑13 and MV4‑11 cell lines, whose MCL level was intermediate, were sensitive to ABT‑737, whereas OCI‑AML3 cells, which exhibited a high MCL‑1 level, were insensitive to ABT‑737. However, multiple AML mouse models and AML cell lines were sensitive to the MCL‑1‑selective antagonist A‑1210477. The results of the present study indicated that the MCL‑1‑selective antagonist could overcome the resistance to the BCL‑2/BCL‑XL antagonist (ABT‑737) in vitro and in vivo.

View Figures

View References

1	Yamaguchi R, Lartigue L and Perkins G: Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Ther. 195:13–20. 2019. View Article : Google Scholar : PubMed/NCBI
2	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
3	Juin P, Geneste O, Gautier F, Depil S and Campone M: Decoding and unlocking the BCL-2 dependency of cancer cells. Nat Rev Cancer. 13:455–465. 2013. View Article : Google Scholar : PubMed/NCBI
4	Adams CM, Clark-Garvey S, Porcu P and Eischen CM: Targeting the Bcl-2 family in B cell lymphoma. Front Oncol. 8:6362019. View Article : Google Scholar : PubMed/NCBI
5	Bhola PD and Letai A: Mitochondria-judges and executioners of cell death sentences. Mol Cell. 61:695–704. 2016. View Article : Google Scholar : PubMed/NCBI
6	Ow TJ, Fulcher CD, Thomas C, Broin PO, López A, Reyna DE, Smith RV, Sarta C, Prystowsky MB, Schlecht NF, et al: Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget. 10:494–510. 2019. View Article : Google Scholar : PubMed/NCBI
7	Gores GJ and Kaufmann SH: Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev. 26:305–311. 2012. View Article : Google Scholar : PubMed/NCBI
8	Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, et al: Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 26:120–125. 2012. View Article : Google Scholar : PubMed/NCBI
9	Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
10	Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, et al: Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma. Oncotarget. 9:16701–16717. 2018. View Article : Google Scholar : PubMed/NCBI
11	Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19:202–208. 2013. View Article : Google Scholar : PubMed/NCBI
12	Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S and Boise LH: Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood. 129:1969–1979. 2017. View Article : Google Scholar : PubMed/NCBI
13	Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, et al: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 26:778–787. 2012. View Article : Google Scholar : PubMed/NCBI
14	Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al: The landscape of somatic copy-number alteration across human cancers. Nature. 463:899–905. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, Leverson JD and Lam LT: Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene. 30:1963–1968. 2011. View Article : Google Scholar : PubMed/NCBI
16	Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, et al: Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 28:58–70. 2014. View Article : Google Scholar : PubMed/NCBI
17	Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, Westerhout EM, Versteeg R, Caron HN, Molenaar JJ and Dolman ME: High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. 7:27946–27958. 2016. View Article : Google Scholar : PubMed/NCBI
18	Lin J, Fu D, Dai Y, Lin J and Xu T: Mcl-1 inhibitor suppresses tumor growth of esophageal squamous cell carcinoma in a mouse model. Oncotarget. 8:114457–114462. 2017.PubMed/NCBI
19	Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al: Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 471:110–114. 2011. View Article : Google Scholar : PubMed/NCBI
20	Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, Izumiya M, Sakai G, Adachi M, Funakoshi S, et al: Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer. 16:100–110. 2013. View Article : Google Scholar : PubMed/NCBI
21	Yecies D, Carlson NE, Deng J and Letai A: Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 115:3304–3313. 2010. View Article : Google Scholar : PubMed/NCBI
22	Song L, Coppola D, Livingston S, Cress D and Haura EB: Mcl-1 regulatessurvival and sensitivity to diverse apoptotic stimuli inhuman non-small cell lung cancer cells. Cancer Biol Ther. 4:267–276. 2005. View Article : Google Scholar : PubMed/NCBI
23	Xiang W, Yang CY and Bai L: MCL-1 inhibition in cancer treatment. Onco Targets Ther. 11:7301–7314. 2018. View Article : Google Scholar : PubMed/NCBI
24	Zhang C, Cai TY, Zhu H, Yang LQ, Jiang H, Dong XW, Hu YZ, Lin NM, He QJ and Yang B: Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther. 10:1264–1275. 2011. View Article : Google Scholar : PubMed/NCBI
25	Stewart ML, Fire E, Keating AE and Walensky LD: The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol. 6:595–601. 2010. View Article : Google Scholar : PubMed/NCBI
26	Placzek WJ, Sturlese M, Wu B, Cellitti JF, Wei J and Pellecchia M: Identification of a novel Mcl-1 protein binding motif. J Biol Chem. 286:39829–39835. 2011. View Article : Google Scholar : PubMed/NCBI
27	Muppidi A, Doi K, Edwardraja S, Drake EJ, Gulick AM, Wang HG and Lin Q: Rational design of proteolytically stable, cell-permeable peptide-based selective Mcl-1 inhibitors. J Am Chem Soc. 134:14734–14737. 2012. View Article : Google Scholar : PubMed/NCBI
28	Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, Andreeff M and Ruvolo PP: Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (−)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 126:363–372. 2015. View Article : Google Scholar : PubMed/NCBI
29	Rheinländer A, Schraven B and Bommhardt U: CD45 in human physiology and clinical medicine. Immunol Lett. 196:22–32. 2018. View Article : Google Scholar : PubMed/NCBI
30	Foight GW, Ryan JA, Gulla SV, Letai A and Keating AE: Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS Chem Biol. 9:1962–1968. 2014. View Article : Google Scholar : PubMed/NCBI
31	Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG and Letai A: Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 151:344–355. 2012. View Article : Google Scholar : PubMed/NCBI
32	Jilg S, Reidel V, Muller-Thomas C, Konig J, Schauwecker J, Hockendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R, et al: Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia. 30:112–123. 2016. View Article : Google Scholar : PubMed/NCBI
33	Tao ZF, Hasvold L, Wang L, Wang X, Petros AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, et al: Discovery of a potent and selective BCL-XL inhibitor with in vivo activity. ACS Med Chem Lett. 5:1088–1093. 2014. View Article : Google Scholar : PubMed/NCBI
34	Bernardo PH, Sivaraman T, Wan KF, Xu J, Krishnamoorthy J, Song CM, Tian L, Chin JS, Lim DS, Mok HY, et al: Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1. J Med Chem. 53:2314–2318. 2010. View Article : Google Scholar : PubMed/NCBI
35	Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X, Roberts-Rapp L, Pappano WN, Elmore SW, Souers AJ, et al: MCL-1 is a key determinant of breast cancer cell survival: Validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 14:1837–1847. 2015. View Article : Google Scholar : PubMed/NCBI
36	Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, et al: BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 28:1657–1665. 2014. View Article : Google Scholar : PubMed/NCBI
37	Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, et al: Key survival factor, Mcl-1, correlates with sensitivity to combined Bcl-2/Bcl-xL blockade. Mol Cancer Res. 15:259–268. 2017. View Article : Google Scholar : PubMed/NCBI
38	Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, Anderson GR, Tingley JP and Wood KC: Targeting MCL-1/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 6:276962016. View Article : Google Scholar : PubMed/NCBI
39	Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, Chen K, Lin H, Taub JW and Ge Y: Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2:170122017. View Article : Google Scholar : PubMed/NCBI